Saniona AB

PRESS RELEASE

March 10, 2021

Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that Rami Levin, President and Chief Executive Officer of Saniona, will present at the Oppenheimer 31^st Annual Healthcare Conference being held virtually March 16-18, 2021.

Details are as follows:
Oppenheimer 31^st Annual Healthcare Conference
Date: March 17, 2021
Time: 9:20 a.m. Eastern Time
Webcast link: https://wsw.com/webcast/oppenheimer9/sanion.st/3758689

The event will be made accessible and archived for approximately 90 days on the Saniona website in the Company Presentations section: https://saniona.com/investors/company-presentations/.

For more information, please contact
Trista Morrison, Chief Communications Officer, Saniona. Office: + 1 (781) 810-9227. Email: trista.morrison@saniona.com

The information was submitted for publication, through the agency of the contact person set out above, at 14.00 CET on 10 March 2021.

About Saniona
Saniona is a biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for rare disease patients around the world. The company’s lead product candidate, Tesomet, is in mid-stage clinical trials for the rare diseases Prader-Willi syndrome and hypothalamic obesity. Saniona also has a broad pipeline derived from its proprietary ion channel discovery platform, with lead candidate SAN711 entering Phase 1 studies for rare neuropathic disorders. Saniona intends to develop and commercialize its rare disease products internally. The company has out-licensed other programs, which may provide future supplemental revenue. Saniona is based in Copenhagen, Denmark and Boston, Mass., U.S. The company’s shares are listed on Nasdaq Stockholm Small Cap (OMX: SANION). Read more at www.saniona.com.

Attachment

• Oppenheimer press release 03.10.21

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.